Peptide Therapeutics CDMO Market By Service, Synthesis Technology, Scale, Application, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035

The global peptide therapeutics contract development and manufacturing organization (CDMO) market is experiencing strong and sustained expansion, supported by increasing demand for peptide-based medicines across metabolic disorders, oncology, and rare diseases. The market is estimated at approximately USD 4.5 billion in 2025 and is projected to reach nearly USD 20 billion by 2035, representing a compound annual growth rate (CAGR) of 16.2% during the 2026-2035 forecast period. This substantial increase reflects the growing number of peptide therapeutics progressing through clinical development and commercialization, as well as the increasing reliance of pharmaceutical and biotechnology companies on specialized external manufacturing partners.

One of the most significant contributors to market expansion is the rapid growth of metabolic therapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based treatments. Rising demand for medicines targeting obesity and type 2 diabetes is creating requirements for substantially larger quantities of peptide active pharmaceutical ingredients (APIs). As successful therapies move into broader commercial use, pharmaceutical companies need scalable synthesis, purification, analytical testing, formulation, and manufacturing capabilities. CDMOs with specialized peptide infrastructure can provide additional capacity and technical expertise, allowing sponsors to respond to increasing market demand without relying exclusively on internal manufacturing facilities.

Noteworthy Market Developments

The peptide therapeutics CDMO market is characterized by strong competition among specialized peptide manufacturers and integrated contract development and manufacturing organizations. Leading companies are expanding their production capacity, investing in advanced synthesis and purification technologies, and strengthening their global manufacturing networks to accommodate increasing demand for complex peptide therapeutics. Their competitive strategies increasingly focus on commercial-scale production, technical expertise, regulatory capabilities, supply-chain reliability, and the ability to support pharmaceutical customers from early development through large-scale manufacturing.

The competitive landscape demonstrates that leading peptide therapeutics CDMOs are pursuing different strategies to capture growing demand. Bachem emphasizes specialized peptide manufacturing and significant capacity expansion, while PolyPeptide Group focuses on its dedicated peptide manufacturing network. CordenPharma differentiates itself through broader end-to-end pharmaceutical manufacturing capabilities, and WuXi TIDES combines peptide specialization with an integrated CRDMO model and expanding global infrastructure. AmbioPharm emphasizes large-scale manufacturing supported by a geographically diversified U.S.-Asia production network.

The market is also moving toward greater integration between development and commercial manufacturing. Pharmaceutical sponsors increasingly seek CDMO partners that can support projects from early-stage peptide development through clinical supply and commercial-scale production, reducing the complexity associated with transferring processes between multiple suppliers. As a result, investments in capacity expansion, automation, purification technologies, analytical infrastructure, and geographically diversified manufacturing networks are expected to remain central to the competitive strategies of major participants in the peptide therapeutics CDMO market.

Core Growth Drivers

The rapid expansion of GLP-1-based therapies has become a major factor supporting growth in the peptide therapeutics contract development and manufacturing organization (CDMO) market. Increasing adoption of GLP-1 receptor agonists for the treatment of type 2 diabetes and obesity has created substantial demand for peptide active pharmaceutical ingredients (APIs), formulation services, analytical testing, and large-scale manufacturing capacity. As these therapies move from clinical development into broad commercial use, pharmaceutical companies are facing significantly higher production requirements, creating additional opportunities for specialized CDMOs with peptide manufacturing expertise.

Emerging Opportunity Trends

AI-driven design paradigms are emerging as an important opportunity within the peptide therapeutics market, with artificial intelligence increasingly being applied to peptide discovery, molecular design, sequence optimization, and preclinical development. AI-based platforms can analyze large biological and chemical datasets to identify sequence patterns, predict molecular behavior, and support the design of peptide candidates with potentially improved therapeutic characteristics. By reducing the dependence on purely trial-and-error approaches, these technologies can help researchers evaluate a larger number of candidate molecules during the early stages of development.

Barriers to Optimization

High manufacturing and purification costs may act as a significant constraint on the growth of the peptide therapeutics CDMO market. The production of therapeutic peptides often requires specialized synthesis equipment, high-quality raw materials, controlled manufacturing environments, advanced analytical systems, and highly skilled technical personnel. Compared with less complex pharmaceutical manufacturing processes, peptide production can involve numerous synthesis and purification steps, increasing overall processing time, resource consumption, and operational expenditure. These cost considerations can become particularly significant as manufacturers move from laboratory and clinical-scale production to larger commercial batches.

Detailed Market Segmentation

By synthesis technology, Solid-Phase Peptide Synthesis (SPPS) represents a major manufacturing approach within the peptide therapeutics CDMO market in 2026. The technology has become widely established for the production of therapeutic peptides because it provides a flexible and scalable platform for assembling amino acid sequences while supporting precise control over individual synthesis steps. Its compatibility with automation, established process-development methodologies, and ability to accommodate increasingly complex peptide structures have contributed to its continued adoption among pharmaceutical companies and specialized CDMOs.

By scale, commercial-scale manufacturing represents a major revenue-generating segment within the peptide therapeutics contract development and manufacturing organization (CDMO) market. The expansion of peptide-based medicines into large commercial markets is increasing demand for high-volume production capabilities, particularly as successful therapies transition from clinical development to routine commercial supply. Once a peptide therapeutic achieves broad market adoption, manufacturing requirements can increase substantially, creating sustained demand for CDMOs with the infrastructure, technical expertise, and regulatory capabilities required to support large-scale production.

By application, metabolic and GLP-1 therapies represent a major demand driver within the peptide therapeutics contract development and manufacturing organization (CDMO) market in 2026. The rapid development and commercialization of incretin-based medicines for metabolic disorders, particularly obesity and type 2 diabetes, have significantly increased demand for peptide synthesis, purification, formulation, analytical testing, and commercial manufacturing services. The expansion of these therapies has created substantial requirements for production capacity, encouraging pharmaceutical companies and biotechnology developers to work with specialized CDMOs to supplement internal manufacturing capabilities.

By end user, large pharmaceutical companies represent a major source of demand within the peptide therapeutics contract development and manufacturing organization (CDMO) market. These companies manage extensive portfolios of branded and generic medicines, including an increasing number of peptide-based therapies that require specialized development and manufacturing capabilities. Although large pharmaceutical organizations typically maintain substantial internal research, development, and manufacturing infrastructure, the growing complexity and volume requirements associated with peptide therapeutics are encouraging greater use of external CDMO services.

Segment Breakdown

By Service

• Peptide API Manufacturing
• Drug Product/Fill-Finish
• Process Development
• Analytical & QC

By Synthesis Technology

• Solid-Phase Peptide Synthesis
• Liquid-Phase Peptide Synthesis
• Hybrid/Recombinant
• Continuous Flow

By Scale

• Preclinical & Clinical
• Commercial

By Application

• Metabolic/GLP-1
• Oncology
• Infectious Disease
• Rare Disease
• Cosmetic
• Others

By End User

• Large Pharma
• Emerging Biopharma
• Generic Manufacturers

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America
• Geography Analysis
• North America holds a leading position in the peptide therapeutics contract development and manufacturing organization (CDMO) market, with the United States and Canada serving as major contributors to regional growth. The region benefits from a highly developed pharmaceutical and biotechnology ecosystem, substantial investment in drug discovery and development, advanced manufacturing capabilities, and the presence of established CDMO providers.
• The United States represents the principal contributor to the regional market, accounting for more than 85% of North American revenue in 2026 according to the stated market estimates. Its strong market position is supported by the concentration of pharmaceutical companies, biotechnology firms, research institutions, and specialized manufacturing organizations across the country.
• Canada also contributes to the broader North American peptide therapeutics manufacturing ecosystem through its pharmaceutical research capabilities, biotechnology sector, specialized manufacturing organizations, and connections with the U.S. market. Canadian companies and research institutions participate in drug discovery, development, clinical research, and pharmaceutical manufacturing activities, creating additional opportunities for CDMOs and related service providers.

Leading Market Participants

• Bachem
• PolyPeptide Group
• Lonza
• Thermo Fisher Scientific (Patheon)
• WuXi AppTec (WuXi TIDES)
• CordenPharma
• Almac Group
• Piramal Pharma Solutions
• Evonik
• Hovione
• Fresenius Kabi
• Ambiopharm
• ScinoPharm
• Peptide Institute
• Sai Life Sciences
• Other Prominent Players